Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 15 , ISSUE 1 ( January-February, 2023 ) > List of Articles

RESEARCH ARTICLE

Ormeloxifene: The Perfect Alternative for the First-line Management of Abnormal Uterine Bleeding

Surbhi Kumari

Keywords : Abnormal uterine bleeding, Centchroman contraception, Ormeloxifene pictorial blood assessment chart Score

Citation Information : Kumari S. Ormeloxifene: The Perfect Alternative for the First-line Management of Abnormal Uterine Bleeding. J South Asian Feder Obs Gynae 2023; 15 (1):85-87.

DOI: 10.5005/jp-journals-10006-2191

License: CC BY-NC 4.0

Published Online: 19-04-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Aim: The aim of this work was to study the role of Ormeloxifene in the management of abnormal uterine bleeding (AUB). Methods: Fifty-one patients with heavy menstrual bleeding with ages between 18 and 50 years were included in the study. The women with post-menopausal bleeding, fibroids, uterus size of more than 8 weeks, polycystic ovarian syndrome (PCOS), and ovarian cysts were excluded. Ormeloxifene (60 mg) twice a week for 12 weeks and then once a week for the next 12 weeks was given to every patient in the study group. The outcome was assessed by the pictorial blood assessment chart (PBAC) score, hemoglobin (HB) level, and endometrial thickness. Results: About 88.24% of patients responded well to treatment as depicted by a significant reduction in the PBAC score to a level <100. The mean PBAC score decreased linearly from 354 to 40 at the end of 24 weeks of treatment. Mean endometrial thickness reduced from 8.25 to 6.01. The mean level of hemoglobin level increased from 11.41 to 11.86. P-value of all the parameters were <0.05 and hence statistically significant. Conclusion: Ormeloxifene can be used as a first-line drug for the management of AUB.

PDF Share
  1. Padubidri VG, Shirish D. Hawkins and Bourne Shaw's Textbook of Gynaecology, Menorrhagia and Dysfunctional Uterine Bleeding, 15th edition, pp. 153–161. Elsevier (Publishers).
  2. Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of Ormeloxifene in management of menorrhagia: A pilot study. J Obstet Gynaecol Res 2009;35:746–752. DOI: 10.1111/j.1447-0756.2008.00987.x.
  3. Speroff L, Fritz MA. Menopause and the perimenopausal transition. Clinical Gynaecology Endocrinology and Infertility, 8th edition. Wolters Kluwer (Publishers).
  4. Prerna S, Verma A, Verma K, et al. Role of Ormeloxifene in management of abnormaluterine bleeding. Sch J App Med Sci 2017;5(3B):796–799. DOI: 10.21276/sjams.2017.5.3.21.
  5. Takreem A, Danish N, Razaq S. Incidence of endometrial hyperplasia in 100 cases presenting with polymenorrhagia/menorrhagia in perimenopausal women. J Ayub Med Col Abbottabad 2009;21:60–63. Corpus ID: 32470567.
  6. ACOG Committee on Practice Bulletins–Gynecology. American College of Obstetricians and Gynecologists. ACOG practice bulletin: Management of anovulatory bleeding. Int J Gynaecol Obstet 2001;72:263–271. DOI: 10.1016/s0020-7292(01)00357-5.
  7. Albers JR, Hull SK, Wesley MA. Abnormal uterine bleeding. Am Fam Phys 2004;69:1915–1926. PMID: 15117012.
  8. Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: A pilot study. Contraception 2002;65(5):325–328. DOI: 10.1016/s0010-7824(02)00283-4.
  9. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone related clinical disorders. Med Res Rev 2001;21:302–347. DOI: 10.1002/med.1011.
  10. Council of Scientific & Industrial Research, available from http://www.csir.res.in. (Assessed on: 12 August 2022).
  11. Kanchan Nisha, Prajwala A. Ormeloxifene in the management of AUB. Int J Clin Obstet Gynaecol 2019;3(2);229–230. DOI: 10.33545/gynae.2019.v3.i2d.41.
  12. Godha Z, Mohsin Z, Hakim S. Comparative study of Ormeloxifene and Medroxyprogesterone acetate in abnormal uterine bleeding. J Obstet Gynaecol India 2016;66(SI):395–399. DOI: 10.1007/s13224-015-0761-2.
  13. Shravage J, Mekhala D, Bellard MB, et al. Ormeloxifene versus medroxyprogesterone acetate (MPA) in the treatment of dysfunctional uterine bleeding: A double-blind randomized controlled trial. South Asian Feder Obstet Gynaecol 2011;3(1):21–24. DOI: 10.5005/jp-journals-10006-1116.
  14. Kriplani A, Srivastava A, Kulshrestha V, et al. Efficacy of ormeloxifene versus oral contraceptive in the management of abnormal uterine bleeding due to uterine leiomyoma. J Obstet Gynaecol Res 2016;42(12):1744–1752. DOI: 10.1111/jog.13105.
  15. Shahab S, Jain S, Jain J, et al. Ormeloxifene: Boon to perimenopausal dysfunctional uterine bleeding (DUB) woman in avoiding hysterectomies. Int J Med Sci Educ 2014;1(1):21–29. Available from: http://www.ijmse.com/uploads/1/4/0/3/14032141/ijmse_2014_vol_1_issue_1_p21-29.pdf.
  16. Arunadevi V, Minnalkodi SNS. Ormeloxifene versus oral contraceptive pills in the management of DUB. Int J Clin Obstet Gynaecol 2020;4(2):81–85. DOI: 10.33545/gynae.2020.v4.i2b.508.
  17. Bhattacharyya TK, Banerji A. Efficacy of a selective estrogen receptor modulator: Ormeloxifene in management of dysfunctional uterine bleeding. South Asian Feder Obstet Gynaecol 2010;2:207–211. DOI: JSAFOG/pdf/10.5005/jp-journals-10006-1100.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.